Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences: 43rd Annual TD Cowen Health Care Conference on Wednesday, March
Fate Therapeutics ( NASDAQ:FATE ) Full Year 2022 Results Key Financial Results Revenue: US$96.3m (up 72% from FY 2021...